Medical Condition News

RSS

UB endocrinologist receives Junior Faculty Award to study effects of low testosterone in young men with type 2 diabetes

An endocrinologist in the University at Buffalo's School of Medicine and Biomedical Sciences has received a three-year $400,000 Junior Faculty Award from the American Diabetes Society to study the effects of low testosterone levels in young men with type 2 diabetes.

30 Oct 2010

Dysfunction of Grhl2 factor may affect epithelial barrier formation, contribute to congenital abnormalities

Scientists of the Max Delbr-ck Center for Molecular Medicine (MDC) Berlin-Buch and the Experimental and Clinical Research Center (ECRC) of MDC and Charit- in Berlin-Buch have gained new insights into the development of epithelial cells and their molecular repertoire.

30 Oct 2010

APP receives FDA marketing approval for Metoprolol Tartrate Injection

APP Pharmaceuticals, Inc., a wholly owned subsidiary of Fresenius Kabi Pharmaceuticals Holding, Inc., announced today that it has received approval from the U.S. Food and Drug Administration (FDA) to market Metoprolol Tartrate Injection, USP, and expects to launch the medication soon.

30 Oct 2010

OHSU to lead next phase of HuCNS-SC trial for NCL in children

Oregon Health & Science University Doernbecher Children's Hospital will lead the next phase of a landmark clinical trial to further assess the safety and preliminary effectiveness of purified human neural stem cells (HuCNS-SC-) as a potential treatment for infantile or late-infantile neuronal ceroid lipofuscinosis (NCL), a rare and currently fatal neurodegenerative disorder that affects infants and children.

30 Oct 2010

FDA approves NUEDEXTA capsules for pseudobulbar affect

AVANIR Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved NUEDEXTA (dextromethorphan hydrobromide and quinidine sulfate) capsules, as the first treatment for pseudobulbar affect.

30 Oct 2010

Study suggests curcumin may be an effective therapy for liver fibrosis

Curcumin, a chemical that gives curry its zing, holds promise in preventing or treating liver damage from an advanced form of a condition known as fatty liver disease, new Saint Louis University research suggests.

30 Oct 2010

CSL Behring creates Interlaken Leadership Awards to support innovative immunoglobulin research

To demonstrate its continued commitment to innovative immunoglobulin (Ig) research, CSL Behring announced today it has created the Interlaken Leadership Awards. This global awards program will provide monetary grants to advance medical research and knowledge about the potential role of immunoglobulin therapy in the treatment of neurologic disorders.

29 Oct 2010

CURE Foundation orders for five Varian TrueBeam stereotactic radiosurgery and radiation therapy systems

Varian Medical Systems, Inc. today announced that CURE Foundation has placed an order for five Varian TrueBeam™ systems for stereotactic radiosurgery and radiation therapy.

29 Oct 2010

Cipher completes enrolment in CIP-ISOTRETINOIN Phase III study for severe, nodular acne

Cipher Pharmaceuticals Inc. today announced that it has completed patient enrolment in its Phase III safety study of CIP-ISOTRETINOIN, the Company's novel, patented formulation of isotretinoin, which is used in the treatment of severe, nodular acne. The Phase III safety study is being conducted under a Special Protocol Assessment that was granted by the U.S. Food and Drug Administration (FDA).

29 Oct 2010

New Chicago Sports Concussion Clinic at Rush University provides proper diagnosis for athletes

Concussions, like any injury, need proper assessment and time to heal. Some may brush off an injury to the head, but an injury to the brain may be severe with possible long-term consequences. Athletes or individuals who suffer a bump or blow to the head now can see a physician for assessment within 24 to 48 hours at the new Chicago Sports Concussion Clinic at Rush University Medical Center.

29 Oct 2010

MAP Pharmaceuticals to present FREEDOM-301 Phase 3 trial data for migraine at EHMTIC Congress

MAP Pharmaceuticals, Inc. today announced new data from the FREEDOM-301 Phase 3 trial of its investigational LEVADEX orally inhaled migraine therapy showing low recurrence rates with LEVADEX. Eight additional analyses from the LEVADEX program also will be presented during the 2010 European Headache and Migraine Trust International Congress (EHMTIC) in Nice, France.

29 Oct 2010

Compugen signs oncology research collaboration agreement with Seattle Genetics

Compugen Ltd. announced today that it has signed a research collaboration agreement with Seattle Genetics, Inc., USA, covering a Compugen-discovered oncology target. The agreement provides Seattle Genetics with an initial evaluation period and an option for an exclusive worldwide milestone and royalty bearing license for development and commercialization of monoclonal antibody therapeutics addressing this novel target.

29 Oct 2010

Study suggests microRNA binding site helps improved prognosis of colorectal cancer at early stage

A variant site linked to poor outcome in advanced colorectal cancer has now been found to predict improved prognosis in early stages of cancer, according to research presented at the American Association for Cancer Research special conference on Colorectal Cancer: Biology to Therapy, held Oct. 27-30, 2010.

29 Oct 2010

Dental health affects control of diabetes

Diabetes is a disease that affects every part of the body, and for people with unstable blood glucose levels there is a higher risk than normal for developing serious complications from poor oral hygiene. In a study by dLife, the world's largest diabetes community, and SoundView Research, Inc., 66 percent of active diabetes managers had not changed their oral care habits since being diagnosed and over half have not been advised by their dentist to take extra care to brush, floss, or rinse daily.

29 Oct 2010

Professionals share ideas on effective ways to educate patients, practitioners and public about cancer

Florence Nightingale once said that apprehension, uncertainty, waiting, expectation and fear of surprise do a patient more harm than any exertion. This valuable philosophy is shared by today's nurses, social workers and other healthcare professionals as they work to educate every patient -- before, during and after their treatment, leaving no question unanswered.

29 Oct 2010

Coherex achieves two milestones in structural heart disease field

In honor of World Stroke Day (October 29, 2010), Coherex Medical, Inc. today announced it has achieved two milestones that further strengthen its position as an emerging medical device company in the field of structural heart disease.

29 Oct 2010

Studies identify effective strategies for improving colorectal cancer screening among African-Americans

African-Americans are less likely than whites to be screened for colorectal cancer, and the disparity almost certainly contributes to higher mortality. A new review of studies identifies effective strategies for improving the situation, but suggests that work remains to be done.

29 Oct 2010

Research on brain circuit activity may pave way to find biomarker for PTSD

University of Minnesota Medical School and Minneapolis Veterans Affair Medical Center researchers have discovered a correlation between increased circuit activity in the right side of the brain and the debilitating, involuntary flashbacks triggered by post traumatic stress disorder (PTSD).

29 Oct 2010

KAST trial to assess Kiva vertebral augmentation treatment for painful VCFs due to osteoporosis

Physicians at The Medical College of Wisconsin are conducting the KAST clinical trial at Froedtert Hospital to assess the safety and effectiveness of a new vertebral augmentation treatment (Kiva) for painful vertebral compression fractures (VCFs) due to osteoporosis.

29 Oct 2010

EUCOMMTOOLS partners to receive 12 million euros research funding from European Commission

The findings will contribute to a better understanding of the pathogenesis of widespread diseases such as Alzheimer's, depression, diabetes, chronic lung diseases or cancer. Over the next five years, the eight EUCOMMTOOLS partners, coordinated by Professor Wolfgang Wurst of Helmholtz Zentrum M-nchen, will receive research funding amounting to approximately 12 million euros from the European Commission.

29 Oct 2010

Medical Condition News

UB endocrinologist receives Junior Faculty Award to study effects of low testosterone in young men with type 2 diabetes

Dysfunction of Grhl2 factor may affect epithelial barrier formation, contribute to congenital abnormalities

APP receives FDA marketing approval for Metoprolol Tartrate Injection

OHSU to lead next phase of HuCNS-SC trial for NCL in children

FDA approves NUEDEXTA capsules for pseudobulbar affect

Study suggests curcumin may be an effective therapy for liver fibrosis

CSL Behring creates Interlaken Leadership Awards to support innovative immunoglobulin research

CURE Foundation orders for five Varian TrueBeam stereotactic radiosurgery and radiation therapy systems

Cipher completes enrolment in CIP-ISOTRETINOIN Phase III study for severe, nodular acne

New Chicago Sports Concussion Clinic at Rush University provides proper diagnosis for athletes

MAP Pharmaceuticals to present FREEDOM-301 Phase 3 trial data for migraine at EHMTIC Congress

Compugen signs oncology research collaboration agreement with Seattle Genetics

Study suggests microRNA binding site helps improved prognosis of colorectal cancer at early stage

Dental health affects control of diabetes

Professionals share ideas on effective ways to educate patients, practitioners and public about cancer

Coherex achieves two milestones in structural heart disease field

Studies identify effective strategies for improving colorectal cancer screening among African-Americans

Research on brain circuit activity may pave way to find biomarker for PTSD

KAST trial to assess Kiva vertebral augmentation treatment for painful VCFs due to osteoporosis

EUCOMMTOOLS partners to receive 12 million euros research funding from European Commission

Discover how SciY empowers scientists

Why use light scattering to analyze proteins and viral vectors?

Changing the landscape of R&D to build clinical success from the ground up

Latest News